Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system ; volume:25 ; number:1 ; day:23 ; month:2 ; year:2024 ; pages:1-9 ; date:12.2024
BMC pharmacology & toxicology ; 25, Heft 1 (23.2.2024), 1-9, 12.2024
- Urheber
-
Zhao, Dehua
Long, Xiaoqing
Wang, Jisheng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-024-00741-x
- URN
-
urn:nbn:de:101:1-2404301309556.918026305647
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhao, Dehua
- Long, Xiaoqing
- Wang, Jisheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia